CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

A lawsuit against the genomics company "imposes top-down restrictions" rather than "establishing clear rules" or "letting ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is spearheading a study titled ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...